Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Mineralys Therapeutics, Inc. (MLYS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$15.24-10.35%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for MLYS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
EPS loss narrowing trajectory | A supporting condition in Mineralys Therapeutics, Inc.'s published investment case. The stated target is EPS loss improves from -0.56 next quarter to less negative by FY27. | Broken | EPS loss worsens or remains flat through FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth and commercial-launch story, not a proven durable compounder. The long-term thesis is on watch: management is on track with launch preparations, but recent financial performance is weak and confidence in the evidence is low.
The snapshot provides no valuation or market-expectations evidence, so whether MLYS is cheap, fair, or expensive versus peers cannot be assessed. It does show weak results and a recent downward price reaction, but that alone does not establish what the market already assumes.
Near term, earnings risk is elevated: MLYS missed its latest quarter, has erratic earnings surprises, and faces a meaningful risk of a guidance cut. Over the multi-year view, launch preparations for lorundrostat are on track toward a December 22, 2026 PDUFA target date, and management says current cash can fund operations into 2028; however, the company remains loss-making.
The thesis depends on launch readiness translating into commercial progress, while the improved economics from eliminating royalty obligations must be weighed against added financing. A guidance cut or further weakening in jobs data could add pressure; continued strength from healthcare bellwethers such as VRTX, REGN, and MRNA would support the sector backdrop.
For the next 1 to 3 years, MLYS is a high-risk launch thesis with encouraging preparation and liquidity evidence, but weak results and uncertain execution leave the case fragile. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Mineralys is advancing the commercial launch of lorundrostat, a key product. |
| Intact |
| failure to advance commercial launch milestones through FY26 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “• Commercial Launch Readiness, The Company is advancing its commercial launch preparations and now has an expanded medical affairs team and sales force in place.” “Brand marketing preparations are well underway, and the Company is finalizing a full-service patient support program designed to ease access for physicians, their office staff and patients.” Operating income was $-60.087 million in 2026-Q3. Delivery assessment Nov 4, 2026 |
Finalize agreement to terminate future royalty payments | The company aims to finalize an agreement to end future royalty payments, improving capital allocation. | Recovered | no agreement finalized by end of 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.10 → $-2.43 · observed estimates
$0.12B → $0.08B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.10 | $121,384,897 | 6 / 6 |
| 2026-07-25 | $-2.10 | $121,384,897 | 6 / 6 |
| 2026-07-26 | $-2.10 | $121,384,897 | 6 / 6 |
| 2026-07-27 | $-2.10 | $121,384,897 | 6 / 6 |
| 2026-07-28 | $-2.10 | $121,384,150 | 8 / 8 |
| 2026-07-29 | $-2.10 | $121,384,150 | 8 / 8 |
| 2026-07-30 | $-2.10 | $121,384,150 | 8 / 8 |
| 2026-07-31 | $-2.10 | $121,384,150 | 8 / 8 |
| 2026-08-01 | $-2.10 | $121,384,147 | 6 / 6 |
| 2026-08-02 | $-2.10 | $121,384,150 | 8 / 8 |
| 2026-08-03 | $-2.10 | $121,384,150 | 8 / 8 |
| 2026-08-04 | $-2.10 | $121,384,150 | 8 / 8 |
| 2026-08-05 | $-2.10 | $121,384,147 | 6 / 6 |
| 2026-08-06 | $-2.10 | $121,384,150 | 8 / 8 |
| 2026-08-07 | $-2.10 | $121,384,147 | 6 / 6 |
| 2026-08-08 | $-2.10 | $121,384,150 | 8 / 8 |
| 2026-08-09 | $-2.10 | $121,384,150 | 8 / 8 |
| 2026-08-10 | $-2.10 | $121,384,150 | 8 / 8 |
| 2026-08-12 | $-2.10 | $121,384,147 | 6 / 6 |
| 2026-08-13 | $-2.10 | $121,384,147 | 6 / 6 |
| 2026-08-14 | $-2.10 | $121,384,147 | 6 / 6 |
| 2026-08-15 | $-2.10 | $121,384,147 | 6 / 5 |
| 2026-08-16 | $-2.10 | $121,384,147 | 6 / 5 |
| 2026-08-17 | $-2.10 | $121,384,147 | 6 / 5 |
| 2026-08-18 | $-2.10 | $121,384,147 | 6 / 6 |
| 2026-08-19 | $-2.10 | $121,384,147 | 6 / 6 |
| 2026-08-20 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-08-21 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-08-22 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-08-23 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-08-24 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-08-25 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-08-26 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-08-27 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-08-28 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-08-29 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-08-30 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-08-31 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-09-01 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-09-02 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-09-03 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-09-04 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-09-05 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-09-06 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-09-07 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-09-08 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-09-09 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-09-10 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-09-11 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-12 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-13 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-14 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-15 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-16 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-17 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-18 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-19 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-20 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-21 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-22 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-23 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-24 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-25 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-26 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-27 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-28 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-29 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-09-30 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-10-01 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-10-02 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-10-03 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-10-04 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-10-05 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-10-06 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-10-07 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-10-08 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-10-09 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-10-10 | $-2.43 | $88,684,546 | 6 / 6 |
| 2026-10-11 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-10-12 | $-2.43 | $88,688,396 | 6 / 6 |
| 2026-10-13 | $-2.39 | $87,833,306 | 7 / 6 |
| 2026-10-14 | $-2.39 | $87,833,306 | 7 / 6 |
| 2026-10-15 | $-2.39 | $87,833,306 | 7 / 6 |
| 2026-10-16 | $-2.39 | $87,833,306 | 7 / 6 |
| 2026-10-17 | $-2.39 | $87,833,306 | 7 / 6 |
| 2026-10-18 | $-2.39 | $87,833,309 | 7 / 6 |
| 2026-10-19 | $-2.39 | $87,833,309 | 7 / 6 |
| 2026-10-20 | $-2.39 | $87,833,309 | 7 / 6 |
| 2026-10-21 | $-2.39 | $87,833,309 | 7 / 6 |
| 2026-10-22 | $-2.39 | $87,833,309 | 7 / 6 |
| 2026-10-23 | $-2.39 | $87,833,309 | 7 / 6 |
| 2026-10-24 | $-2.39 | $87,833,309 | 7 / 6 |
| 2026-10-25 | $-2.39 | $87,833,309 | 7 / 6 |
| 2026-10-26 | $-2.39 | $87,833,309 | 7 / 6 |
| 2026-10-27 | $-2.39 | $87,833,309 | 7 / 6 |
| 2026-10-28 | $-2.39 | $87,833,309 | 7 / 6 |
| 2026-10-29 | $-2.39 | $87,833,309 | 7 / 6 |
| 2026-10-30 | $-2.39 | $87,833,309 | 7 / 6 |
| 2026-10-31 | $-2.43 | $84,333,309 | 7 / 6 |
| 2026-11-01 | $-2.43 | $84,333,309 | 7 / 6 |
| 2026-11-02 | $-2.43 | $84,333,309 | 7 / 6 |
| 2026-11-03 | $-2.43 | $84,333,309 | 7 / 6 |
| 2026-11-04 | $-2.43 | $84,333,309 | 6 / 6 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 9 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.